References
- WHO. World Health Organisation: data and statistics; causes of death. 2004, available at: http://www.who.int/healthinfo/statistics/ bodgbddeathdalyestimates.xls
- Usui Y, Sauvage LR, Wu HD, Goff SG, Walker M. A comparativeexperimental study of the organization of arterial and venous thrombi. Ann Surg 1987; 205 (3): 312–317.
- Kristensen SD, Ravn HB, Falk E. Insights into the pathophysiol-ogy of unstable coronary artery disease. Am J Cardiol 1997; 80 (5A): 5E–9E.
- McBane RD 2nd, Karnicki K, Tahirkheli N, Miller RS, Owen WG. Platelet characteristics associated with coronary artery disease. J Thromb Haemost 2003; 1(6): 1296–303.
- Ault KA, Cannon CP, Mitchell J et al. Platelet activation in patients after an acute coronary syndrome: results from the TIMI-12 trial. J Am Coll Cardiol 1999; 33 (3): 634–639.
- Rautaharju PM, Prineas RJ, Eifler WJ et al. Prognostic value of exercise electrocardiogram in men at high risk of future coronary heart disease: multiple Risk Factor Intervention Trial experience. J Am Coll Cardiol 1986; 8 (1): 1–10.
- Ekelund, LG, Suchindran CM, McMahon RP et al. Coronary heart disease morbidity and mortality in hypercholesterolemic men predicted from an exercise test: the Lipid Research Clinics Coronary Primary Prevention Trial. J Am Coll Cardiol 1989; 14 (3): 556–563.
- Michelson AD. Flow cytometry: a clinical test of platelet function.Blood 1996; 87 (12): 4925–4936.
- Michelson AD, Furman MI. Laboratory markers of platelet activation and their clinical significance. Curr Opin Hematol 1999; 6 (5): 342–348.
- Macey MG, Carty E, Webb L et al. Use of mean platelet component to measure platelet activation on the ADVIA 120 haematology system. Cytometry 1999; 38 (5): 250–255.
- Ahnadi CE, Sabrinah Chapman E, Lépine M et al. Assessment of platelet activation in several different anticoagulants by the Advia 120 Hematology System, fluorescence flow cytometry, and electron microscopy. Thromb Haemost 2003; 90 (5): 940–948.
- Boos CJ, Beevers GD, Lip GY. Assessment of platelet activation indices using the ADVIATM 120 amongst 'high-risk' patients with hypertension. Ann Med 2007; 39 (1): 72–78.
- Furman MI, Benoit SE, Barnard MR et al. Increased platelet reactivity and circulating monocyte-platelet aggregates in patients with stable coronary artery disease. J Am Coll Cardiol 1998; 31(2): 352–358.
- Cahill MR, Macey MG, Dawson JR, et al. Platelet surface activation antigen expression at baseline and during elective angioplasty in patients with mild to moderate coronary artery disease. Blood Coagul Fibrinolysis 1996; 7 (2): 165–168.
- Boos CJ, Balakrishnan B, Lip GY. The effects of coronary artery disease severity on time-dependent changes in platelet activation indices in stored whole blood. J Thromb Thrombolysis 2008; 25 (2): 135–140.